Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 6 | 2022 | 222 | 2.320 |
Why?
|
| Humans | 56 | 2023 | 18430 | 1.860 |
Why?
|
| Vaccination | 12 | 2022 | 674 | 1.560 |
Why?
|
| Ethnic Groups | 5 | 2021 | 501 | 1.520 |
Why?
|
| Hospitalization | 9 | 2022 | 847 | 1.490 |
Why?
|
| Urinary Tract Infections | 4 | 2022 | 21 | 1.480 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 567 | 1.420 |
Why?
|
| Coccidioidomycosis | 2 | 2020 | 5 | 1.340 |
Why?
|
| Meningococcal Vaccines | 4 | 2019 | 46 | 1.300 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 142 | 1.290 |
Why?
|
| California | 19 | 2022 | 2365 | 1.280 |
Why?
|
| Male | 32 | 2023 | 10440 | 1.270 |
Why?
|
| Child | 17 | 2022 | 2571 | 1.260 |
Why?
|
| Influenza, Human | 3 | 2022 | 282 | 1.210 |
Why?
|
| Female | 34 | 2023 | 13136 | 1.170 |
Why?
|
| Retrospective Studies | 15 | 2022 | 2550 | 1.090 |
Why?
|
| Adolescent | 17 | 2022 | 3798 | 1.070 |
Why?
|
| Child, Preschool | 13 | 2022 | 1478 | 1.030 |
Why?
|
| Adult | 22 | 2023 | 7910 | 1.000 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2015 | 14 | 0.990 |
Why?
|
| RNA, Messenger | 2 | 2022 | 80 | 0.980 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2016 | 64 | 0.930 |
Why?
|
| Seizures, Febrile | 2 | 2014 | 47 | 0.920 |
Why?
|
| Herpes Zoster | 5 | 2016 | 88 | 0.900 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 382 | 0.880 |
Why?
|
| Aged | 19 | 2022 | 6417 | 0.870 |
Why?
|
| Streptococcal Infections | 3 | 2014 | 22 | 0.850 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 10 | 0.840 |
Why?
|
| Infant | 11 | 2022 | 1245 | 0.830 |
Why?
|
| Tuberculosis | 1 | 2022 | 20 | 0.830 |
Why?
|
| United States | 14 | 2023 | 4164 | 0.830 |
Why?
|
| Whooping Cough | 4 | 2022 | 75 | 0.820 |
Why?
|
| Young Adult | 13 | 2021 | 2518 | 0.810 |
Why?
|
| Orthopedic Procedures | 1 | 2022 | 6 | 0.810 |
Why?
|
| Outpatients | 2 | 2020 | 111 | 0.800 |
Why?
|
| Durable Medical Equipment | 1 | 2021 | 1 | 0.780 |
Why?
|
| Middle Aged | 20 | 2022 | 8284 | 0.750 |
Why?
|
| Minority Groups | 1 | 2021 | 105 | 0.730 |
Why?
|
| Cohort Studies | 11 | 2023 | 2672 | 0.720 |
Why?
|
| Antifungal Agents | 1 | 2020 | 4 | 0.720 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.710 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.680 |
Why?
|
| Health Status Disparities | 1 | 2021 | 153 | 0.680 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.680 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 157 | 0.650 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 2003 | 0.640 |
Why?
|
| Coccidioides | 1 | 2018 | 3 | 0.630 |
Why?
|
| Vaccines, Conjugate | 3 | 2019 | 66 | 0.620 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 290 | 0.620 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 24 | 0.610 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2022 | 95 | 0.600 |
Why?
|
| Incidence | 8 | 2022 | 1314 | 0.590 |
Why?
|
| Meningitis, Meningococcal | 2 | 2017 | 7 | 0.590 |
Why?
|
| Obesity | 2 | 2021 | 855 | 0.580 |
Why?
|
| Escherichia coli | 2 | 2007 | 5 | 0.570 |
Why?
|
| Bacteremia | 2 | 2013 | 15 | 0.560 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.540 |
Why?
|
| Cross Infection | 1 | 2015 | 28 | 0.520 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 15 | 0.500 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 49 | 0.500 |
Why?
|
| Streptococcus | 2 | 2014 | 2 | 0.500 |
Why?
|
| Pharyngitis | 2 | 2010 | 11 | 0.470 |
Why?
|
| Bacterial Typing Techniques | 3 | 2010 | 3 | 0.460 |
Why?
|
| Bordetella | 1 | 2013 | 1 | 0.460 |
Why?
|
| Bordetella Infections | 1 | 2013 | 1 | 0.460 |
Why?
|
| Risk Factors | 8 | 2020 | 3449 | 0.460 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 15 | 0.450 |
Why?
|
| Neisseria meningitidis | 1 | 2013 | 11 | 0.440 |
Why?
|
| Livestock | 2 | 2020 | 2 | 0.440 |
Why?
|
| Fever | 3 | 2022 | 60 | 0.390 |
Why?
|
| Streptococcus pyogenes | 1 | 2010 | 6 | 0.370 |
Why?
|
| Carrier State | 1 | 2010 | 8 | 0.370 |
Why?
|
| Case-Control Studies | 3 | 2022 | 1173 | 0.360 |
Why?
|
| Genetic Variation | 1 | 2010 | 87 | 0.360 |
Why?
|
| Hospitals | 3 | 2022 | 80 | 0.350 |
Why?
|
| Time Factors | 3 | 2021 | 1136 | 0.350 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 89 | 0.340 |
Why?
|
| Ambulatory Care | 2 | 2022 | 266 | 0.330 |
Why?
|
| Agriculture | 1 | 2018 | 7 | 0.330 |
Why?
|
| Occupational Health | 1 | 2018 | 21 | 0.320 |
Why?
|
| Access to Information | 1 | 2018 | 13 | 0.320 |
Why?
|
| Pandemics | 2 | 2020 | 292 | 0.310 |
Why?
|
| Public Health | 1 | 2018 | 82 | 0.310 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2007 | 1 | 0.300 |
Why?
|
| Fimbriae Proteins | 1 | 2007 | 1 | 0.300 |
Why?
|
| Animals | 4 | 2020 | 261 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 38 | 0.290 |
Why?
|
| Algorithms | 2 | 2022 | 241 | 0.280 |
Why?
|
| Sex Factors | 3 | 2020 | 661 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 53 | 0.280 |
Why?
|
| Body Mass Index | 2 | 2021 | 974 | 0.270 |
Why?
|
| Age Factors | 3 | 2020 | 965 | 0.270 |
Why?
|
| Headache | 2 | 2022 | 14 | 0.270 |
Why?
|
| Myalgia | 2 | 2022 | 10 | 0.270 |
Why?
|
| Escherichia coli Proteins | 1 | 2005 | 1 | 0.270 |
Why?
|
| Comorbidity | 2 | 2020 | 619 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 412 | 0.260 |
Why?
|
| Clostridium difficile | 2 | 2015 | 23 | 0.250 |
Why?
|
| Brazil | 4 | 2014 | 6 | 0.240 |
Why?
|
| Odds Ratio | 2 | 2018 | 701 | 0.230 |
Why?
|
| Neutralization Tests | 1 | 2022 | 3 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 6 | 0.210 |
Why?
|
| Chest Pain | 1 | 2022 | 14 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2015 | 185 | 0.210 |
Why?
|
| Fatigue | 1 | 2022 | 35 | 0.210 |
Why?
|
| Lactams | 1 | 2022 | 1 | 0.210 |
Why?
|
| Leucine | 1 | 2022 | 3 | 0.210 |
Why?
|
| Proline | 1 | 2022 | 5 | 0.210 |
Why?
|
| Ritonavir | 1 | 2022 | 7 | 0.210 |
Why?
|
| Nitriles | 1 | 2022 | 7 | 0.210 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 38 | 0.210 |
Why?
|
| DNA, Bacterial | 3 | 2013 | 9 | 0.210 |
Why?
|
| Drug Combinations | 1 | 2022 | 43 | 0.210 |
Why?
|
| Diphtheria | 1 | 2022 | 14 | 0.210 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 65 | 0.210 |
Why?
|
| Tetanus | 1 | 2022 | 18 | 0.210 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2022 | 14 | 0.200 |
Why?
|
| Influenza A virus | 1 | 2022 | 14 | 0.200 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 80 | 0.200 |
Why?
|
| Organizations | 1 | 2021 | 10 | 0.200 |
Why?
|
| Age Distribution | 3 | 2020 | 261 | 0.200 |
Why?
|
| Aftercare | 1 | 2022 | 48 | 0.190 |
Why?
|
| Electricity | 1 | 2021 | 2 | 0.190 |
Why?
|
| Electronic Health Records | 3 | 2022 | 747 | 0.190 |
Why?
|
| Poverty Areas | 2 | 2010 | 22 | 0.180 |
Why?
|
| Seasons | 2 | 2022 | 105 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 58 | 0.180 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2020 | 8 | 0.180 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 5 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2022 | 153 | 0.180 |
Why?
|
| Immunization Schedule | 3 | 2019 | 133 | 0.170 |
Why?
|
| Meningococcal Infections | 1 | 2019 | 17 | 0.170 |
Why?
|
| Medicaid | 1 | 2021 | 211 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2020 | 198 | 0.170 |
Why?
|
| Population Surveillance | 3 | 2022 | 271 | 0.170 |
Why?
|
| Continental Population Groups | 1 | 2021 | 315 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 407 | 0.160 |
Why?
|
| Immunoassay | 1 | 2018 | 9 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2020 | 1143 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1269 | 0.150 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 46 | 0.150 |
Why?
|
| Asthma | 1 | 2020 | 390 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 350 | 0.140 |
Why?
|
| Escherichia coli Infections | 2 | 2007 | 6 | 0.140 |
Why?
|
| Risk | 2 | 2015 | 552 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 116 | 0.140 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 15 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 444 | 0.140 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.130 |
Why?
|
| Policy Making | 1 | 2016 | 18 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 743 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2015 | 94 | 0.130 |
Why?
|
| Hypertension | 1 | 2020 | 524 | 0.130 |
Why?
|
| Immunocompetence | 1 | 2015 | 10 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 530 | 0.130 |
Why?
|
| Vaccine Potency | 1 | 2015 | 5 | 0.130 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2015 | 30 | 0.130 |
Why?
|
| Managed Care Programs | 2 | 2014 | 347 | 0.120 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.120 |
Why?
|
| Inpatients | 1 | 2015 | 80 | 0.120 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.120 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 8 | 0.120 |
Why?
|
| Genotype | 2 | 2014 | 253 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 151 | 0.120 |
Why?
|
| Maternal Age | 1 | 2014 | 80 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 65 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2016 | 162 | 0.120 |
Why?
|
| Recurrence | 1 | 2014 | 187 | 0.120 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2013 | 1 | 0.110 |
Why?
|
| Molecular Typing | 1 | 2013 | 1 | 0.110 |
Why?
|
| Spleen | 1 | 2013 | 4 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2014 | 319 | 0.110 |
Why?
|
| Gestational Age | 1 | 2014 | 119 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2014 | 43 | 0.110 |
Why?
|
| Urban Population | 2 | 2012 | 124 | 0.110 |
Why?
|
| Africa South of the Sahara | 1 | 2013 | 2 | 0.110 |
Why?
|
| Models, Immunological | 1 | 2013 | 3 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 4 | 0.110 |
Why?
|
| Mass Vaccination | 1 | 2013 | 22 | 0.110 |
Why?
|
| Minnesota | 1 | 2013 | 54 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 118 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2013 | 134 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2013 | 120 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 97 | 0.110 |
Why?
|
| Oregon | 1 | 2013 | 222 | 0.100 |
Why?
|
| HIV Infections | 1 | 2019 | 695 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 1 | 0.100 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2012 | 1 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 476 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 4 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 20 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 598 | 0.100 |
Why?
|
| Cities | 1 | 2012 | 29 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 399 | 0.100 |
Why?
|
| Prevalence | 2 | 2012 | 911 | 0.100 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 7 | 0.090 |
Why?
|
| Chickens | 1 | 2020 | 6 | 0.090 |
Why?
|
| Neoplasms | 1 | 2014 | 457 | 0.080 |
Why?
|
| Community-Based Participatory Research | 1 | 2018 | 63 | 0.080 |
Why?
|
| Sequence Homology | 1 | 2007 | 1 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1296 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2014 | 848 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2007 | 96 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 1360 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2022 | 872 | 0.070 |
Why?
|
| Cattle | 1 | 2005 | 6 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 18 | 0.070 |
Why?
|
| African Americans | 2 | 2020 | 490 | 0.060 |
Why?
|
| Cough | 1 | 2022 | 22 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Temperature | 1 | 2022 | 18 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 45 | 0.050 |
Why?
|
| Influenza B virus | 1 | 2022 | 8 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2022 | 57 | 0.050 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2022 | 56 | 0.050 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 35 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2019 | 70 | 0.040 |
Why?
|
| Asian Americans | 1 | 2020 | 182 | 0.040 |
Why?
|
| Vaccines, Combined | 1 | 2019 | 91 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 135 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 428 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 554 | 0.040 |
Why?
|
| Bell Palsy | 1 | 2017 | 17 | 0.040 |
Why?
|
| Pregnancy | 1 | 2022 | 1516 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 101 | 0.030 |
Why?
|
| Stroke | 1 | 2019 | 311 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 64 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 59 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Superantigens | 1 | 2014 | 1 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2014 | 1 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 7 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 20 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 21 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2014 | 19 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 27 | 0.030 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 2 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2012 | 4 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 318 | 0.020 |
Why?
|
Concepts
(245)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->